The company is now a liquidating shell with no operating business. The only remaining value for stakeholders is the contingent milestone payments tied to Teva's success with IGALMI at-home use. Monitor FDA action on the sNDA (PDUFA date referenced as November 21, 2026) and Teva's commercialization efforts for any milestone realization.
Price Chart
Executive Summary
BioXcel Therapeutics completed the sale of substantially all of its neuroscience assets to Teva Pharmaceuticals for $57.5 million upfront cash, plus contingent milestone payments of up to $67.5 million tied to FDA approval of IGALMI for at-home use and up to $20 million in commercial milestones. The sale closed through a Chapter 11 bankruptcy process, and the company terminated its CEO, CFO, CSO, and CLO, appointed its Chief Restructuring Officer as President, and authorized a name change to BX Liquidation, Inc. to wind down.
Key Facts
- Teva acquired substantially all of BioXcel's neuroscience assets, including IGALMI (dexmedetomidine) and BXCL501, related IP, and regulatory filings including the sNDA for at-home use.
- Upfront cash consideration was $57.5 million, with a $5.75 million deposit credited.
- BioXcel is eligible for a development milestone payment of up to $67.5 million contingent on FDA approval of the sNDA for IGALMI at-home use, with amounts decreasing based on timing.
- If FDA approval is not obtained by February 28, 2027, BioXcel is eligible for commercial milestone payments of up to $20 million total, tied to net sales thresholds of $250 million and $500 million.
- BioXcel retained rights to BXCL701 and BXCL702, which were excluded from the sale.
- Sale proceeds were applied to repay debtor-in-possession financing obligations.
- CEO Vimal Mehta, CFO Richard Steinhart, CSO Frank Yocca, and CLO Javier Rodriguez were terminated effective October 31, 2026.
- Samir Saleem, Chief Restructuring Officer, was appointed President and Secretary and will serve as principal executive officer.
- The company authorized a name change to BX Liquidation, Inc. in advance of wind-down and liquidation.
- Trading in BioXcel common stock was suspended on Nasdaq on September 8, 2026, and now trades on OTC Pink under symbol BTAIQ.
Financial Impact
Upfront cash of $57.5 million, plus up to $67.5 million in development milestones and up to $20 million in commercial milestones, totaling up to $145 million in potential consideration.
Risk Factors
- The company is in Chapter 11 wind-down with no ongoing business; common stock is trading on OTC Pink with delisting risk.
- Contingent milestone payments are highly uncertain and depend on FDA approval and Teva's commercial execution.
- All senior management has been terminated; the company has no operating infrastructure.
- Proceeds from the sale were used to repay DIP financing, leaving minimal recovery for equity holders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-120737 |
| Document: tm2624733d2_ex99-1.htm | 0001104659-26-120737 |
| Document: tm2624733d2_8k.htm | 0001104659-26-120737 |
| Document: tm2624733d2_ex3-1.htm | 0001104659-26-120737 |
| Document: 0001104659-26-120737-index-headers.html | 0001104659-26-120737 |
| Document: 0001104659-26-120737-index.html | 0001104659-26-120737 |
| Document: 0001104659-26-120737.txt | 0001104659-26-120737 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers